NC
IMVT icon

NewSquare Capital’s Immunovant IMVT Stock Holding History

NewSquare Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50
Closed -$949 – 735
2023
Q2 		$949 Hold
50
– – ﹤0.01% 617
2023
Q1 		$776 Hold
50
– – ﹤0.01% 679
2022
Q4 		$888 Buy
+50
New +$630 ﹤0.01% 589

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

NewSquare Capital's IMVT Position: Q3 2023 in Review

NewSquare Capital sold out of Immunovant (IMVT) in Q3 2023, closing a stake of 50 shares — an estimated $949 sold.

NewSquare Capital first reported a position in IMVT in Q4 2022 and held it in 3 quarters. The position peaked at $949 in Q2 2023. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2023.

  • NewSquare Capital reported no remaining Immunovant position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 50 Immunovant shares in Q3 2023, an estimated $949.
  • NewSquare Capital first reported a position in Immunovant in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Immunovant position peaked at $949 in Q2 2023.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.